Get the Stockscreener App
2.49
6.39%
-0.17
After Hours:
2.51
0.02
+0.80%
Kalaris Therapeutics Inc stock is traded at $2.49, with a volume of 61,997.
It is down -6.39% in the last 24 hours and up +2.47% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$2.66
Open:
$2.5845
24h Volume:
61,997
Relative Volume:
1.29
Market Cap:
$46.57M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.35%
1M Performance:
+2.47%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.46
$2.59
1-Week Range:
$2.46
$2.7932
52-Week Range:
$2.28
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
628 MIDDLEFIELD ROAD, PALO ALTO
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
2.49 | 49.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Is Kalaris Therapeutics Inc. Forming a Bottom Pattern [July 2025 Pullbacks]Technical Pattern Based Buy Signals - beatles.ru
What moving averages say about Kalaris Therapeutics Inc.Oversold Opportunity Scanner with RSI Data - Newser
Using AI based signals to follow Kalaris Therapeutics Inc.Intelligent Trade Forecast With AI Analytics - Newser
Is Kalaris Therapeutics Inc. stock entering bullish territoryMomentum Trading Guide with Safety Limits - Newser
Can swing trading help recover from Kalaris Therapeutics Inc. lossesPredictable Income Summary for Long-Term Trades - Newser
How to integrate Kalaris Therapeutics Inc. into portfolio analysis toolsLong Term Equity Screener with Safety Metrics - Newser
Using Ichimoku Cloud for Kalaris Therapeutics Inc. technicalsSmart Entry Watchlist with Daily Analysis - Newser
What makes Kalaris Therapeutics Inc. stock price move sharplyImmediate Entry Point Prediction Strategy - Newser
Will Kalaris Therapeutics Inc. bounce back from current supportFree Breakout Entry Signal Confirmation Tool - Newser
How Kalaris Therapeutics Inc. stock performs during market volatilitySector Rotation and Stock Opportunity Analysis - Newser
Automated trading signals detected on Kalaris Therapeutics Inc.Free Weekly Top Gainers Forecast Watchlist - Newser
Will earnings trigger a reversal in Kalaris Therapeutics Inc.Free Low Volatility Stable Growth Picks - Newser
Has Kalaris Therapeutics Inc. formed a bullish divergenceReal Time Alert System for Market Moves - Newser
Why Kalaris Therapeutics Inc. stock attracts strong analyst attentionIntelligent Trade Forecast With AI Analytics - Newser
Multi asset correlation models including Kalaris Therapeutics Inc.Real Time Trade Execution Alert Plan - Newser
Using economic indicators to assess Kalaris Therapeutics Inc. potentialChart Confirmation Setup with ROI Signals - Newser
Is Kalaris Therapeutics Inc. stock a good hedge against inflationAnnual Market Behavior and Sector Summary - Newser
Should I buy Kalaris Therapeutics Inc. stock before earningsAlpha Trade Flow With Risk Calibration - Newser
Will Kalaris Therapeutics Inc. continue its uptrendMachine Learning Stock Price Forecast Tool - Newser
Kalaris KLRS 2025Q2 Earnings Preview Upside Potential on Analyst Price Target Predictions - AInvest
Applying Elliott Wave Theory to Kalaris Therapeutics Inc.Watchlist Summary for Active Day Traders - Newser
What analysts say about Kalaris Therapeutics Inc. stockHigh-yield trading alerts - Jammu Links News
How volatile is Kalaris Therapeutics Inc. stock compared to the marketUnlock powerful trading tools for investors - Jammu Links News
Is it the right time to buy Kalaris Therapeutics Inc. stockInvest confidently with data-driven strategies - Jammu Links News
What is the risk reward ratio of investing in Kalaris Therapeutics Inc. stockNavigate the market with precision insights - Jammu Links News
How many analysts rate Kalaris Therapeutics Inc. as a “Buy”Consistently superior profits - Jammu Links News
Why is Kalaris Therapeutics Inc. stock attracting strong analyst attentionExceptional stock performance - Jammu Links News
What institutional investors are buying Kalaris Therapeutics Inc. stockCapitalize on trading strategies that deliver - Jammu Links News
What are the latest earnings results for Kalaris Therapeutics Inc.High-velocity gains - Jammu Links News
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):